|840.14 -9.04 (-1.06%)||12-08 16:00|
|Targets||6-month :||993.12||1-year :||1159.96|
|Resists||First :||850.27||Second :||993.12|
|Supports||First :||809.05||Second :||783.57|
|MAs||MA(5) :||833.85||MA(20) :||809.74|
|MA(100) :||807.77||MA(250) :||776.52|
|MACD||MACD :||7.5||Signal :||2.5|
|%K %D||K(14,3) :||89.9||D(3) :||88.6|
|52-week||High :||853.96||Low :||668|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ REGN ] has closed below upper band by 10.8%. Bollinger Bands are 19.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||849.01 - 853.48||853.48 - 857.29|
|Low:||828.8 - 833.94||833.94 - 838.32|
|Close:||831.76 - 840.42||840.42 - 847.79|
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||107 (M)|
|Shares Float||102 (M)|
|Held by Insiders||2.5 (%)|
|Held by Institutions||89.4 (%)|
|Shares Short||1,400 (K)|
|Shares Short P.Month||1,370 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||234.46|
|Profit Margin||30.4 %|
|Operating Margin||36 %|
|Return on Assets (ttm)||9.2 %|
|Return on Equity (ttm)||17.2 %|
|Qtrly Rev. Growth||14.5 %|
|Gross Profit (p.s.)||65.52|
|Sales Per Share||122.28|
|Qtrly Earnings Growth||-23.8 %|
|Operating Cash Flow||5,220 (M)|
|Levered Free Cash Flow||3,530 (M)|
|Price to Book value||3.58|
|Price to Sales||6.87|
|Price to Cash Flow||17.24|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|